Table of Contents Author Guidelines Submit a Manuscript
Interdisciplinary Perspectives on Infectious Diseases
Volume 2012, Article ID 646480, 5 pages
http://dx.doi.org/10.1155/2012/646480
Clinical Study

In Vitro Activities of Ertapenem and Imipenem against Clinical Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae Collected in Military Teaching Hospital Mohammed V of Rabat

1Department of Bacteriology, Military Teaching Hospital Mohammed V and Faculty of Medicine and Pharmacy, Mohammed V University, Souissi, Rabat, Morocco
2Laboratory of Biostatistics, Faculty of Medicine and Pharmacy, Mohammed V University, Souissi, Rabat, Morocco
3Study Research Group for Antibiotic Resistance and Bacterial Infections, Faculty of Medicine and Pharmacy, Mohammed V University, Souissi, Rabat, Morocco

Received 5 February 2012; Accepted 2 May 2012

Academic Editor: Abiola C. Senok

Copyright © 2012 M. Elouennass et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Pitout and K. B. Laupland, “Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern,” The Lancet Infectious Diseases, vol. 8, no. 3, pp. 159–166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Cantón, A. Novais, A. Valverde et al., “Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe,” Clinical Microbiology and Infection, vol. 14, no. 1, pp. 144–153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Rodríguez-Baño and M. D. Ngugro, “Extended-spectrum β-lactamases in ambulatory care: a clinical perspective,” Clinical Microbiology and Infection, vol. 14, no. 1, pp. 104–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Gupta and P. Datta, “Extended-spectrum beta-lactamases (ESBL) in community isolates from North India: frequency and predisposing factors,” International Journal of Infectious Diseases, vol. 11, no. 1, pp. 88–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Cattoir and C. Daurel, “Update on antimicrobial chemotherapy?” Medecine et Maladies Infectieuses, vol. 40, no. 3, pp. 135–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Durrmeyer and R. Cohen, “Pediatric use of carbapenems,” Archives de Pediatrie, vol. 17, no. 4, pp. S163–S170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. G. A. Jacoby and L. S. Munoz-Price, “The new beta-lactamases,” The New England Journal of Medicine, vol. 352, no. 4, pp. 380–391, 2005. View at Google Scholar · View at Scopus
  8. A. Endimiani, F. Luzzaro, M. Perilli et al., “. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin,” Clinical Infectious Diseases, vol. 38, no. 2, pp. 243–251, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. D. L. Paterson, W. C. Ko, A. V. Gottberg et al., “Antibi-otic therapy for Klebsiella pneumoniae bacteraemia: implications of production of extended-spectrum beta-lactamases,” Clinical Infectious Diseases, vol. 39, pp. 31–37, 2003. View at Google Scholar
  10. V. Miriagou, G. Cornaglia, M. Edelstein et al., “Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues,” Clinical Microbiology and Infection, vol. 16, no. 2, pp. 112–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Benouda, O. Touzani, M. T. Khairallah, G. F. Araj, and G. M. Matar, “First detection of oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Morocco,” Annals of Tropical Medicine and Parasitology, vol. 104, no. 4, pp. 327–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. J. Soussy, Comité de l’Antibiogramme de la Société Française de Microbiologie, Recommandations, 2010.
  13. K. Lee, Y. Chong, H. B. Shin, Y. A. Kim, D. Yong, and J. H. Yum, “Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species,” Clinical Microbiology and Infection, vol. 7, no. 2, pp. 88–91, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Castanheira, H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones, “Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β- lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 570–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. P. Hyle, M. J. Ferraro, M. Silver, H. Lee, and D. C. Hooper, “Ertapenem-resistant enterobacteriaceae: risk factors for acquisition and outcomes,” Infection Control and Hospital Epidemiology, vol. 31, no. 12, pp. 1242–1249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. N. Jones, H. K. Huynh, and D. J. Biedenbach, “Activities of doripenem (S-4661) against drug-resistant clinical pathogens,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 3136–3140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bassetti, E. Righi, R. Fasce et al., “Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing organisms in an intensive care unit,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 2, pp. 433–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Bazaz, A. L. N. Chapman, and T. G. Winstanley, “Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-βlactamase-producing Gram-negative organisms,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 7, Article ID dkq152, pp. 1510–1513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. C. Lye, L. Wijaya, J. Chan, P. T. Chew, and S. L. Yee, “Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia,” Annals of the Academy of Medicine Singapore, vol. 37, no. 10, pp. 831–834, 2008. View at Google Scholar · View at Scopus
  20. M. L. Berg, C. W. Crank, A. H. Philbrick, and M. K. Hayden, “Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing gram-negative infections: a case series report,” Annals of Pharmacotherapy, vol. 42, no. 2, pp. 207–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Skurnik, S. Lasocki, S. Bremont et al., “Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum β-lactamase,” Journal of Medical Microbiology, vol. 59, no. 1, pp. 115–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Elliott, A. J. Brink, J. van Greune et al., “In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase,” Clinical Infectious Diseases, vol. 42, no. 11, pp. e95–98, 2006. View at Google Scholar · View at Scopus
  23. A. L. L. M. Lima, P. R. Domingos de Oliveira, A. P. de Paula et al., “Carbapenem stewardship—positive impact on hospital ecology,” Brazilian Journal of Infectious Diseases, vol. 15, no. 1, pp. 1–5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. K. J. Eagye and D. P. Nicolau, “Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals,” Infection Control and Hospital Epidemiology, vol. 31, no. 5, pp. 485–490, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. J. C. Goldstein, D. M. Citron, V. Peraino, T. Elgourt, A. R. Meibohm, and S. Lu, “Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5122–5126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. L. L. Lima, P. R. Oliveira, A. P. Paula, K. Dal-Paz, F. Rossi, and A. V. Zumiotti, “The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study,” Infection Control and Hospital Epidemiology, vol. 30, no. 5, pp. 487–490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Crank, B. Hota, and J. Segreti, “Effect of ertapenem utilisation on Pseudomonas aeruginosa susceptibility to imipenem,” in Proceedings of the Program and abstracts of the 44th Annual Meeting Infectious Dis-eases Society of America, abstract 285, 2006.
  28. D. M. Livermore, S. Mushtaq, and M. Warner, “Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 3, pp. 306–311, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. K. J. Eagye and D. P. Nicolau, “Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 6, Article ID dkr141, pp. 1392–1395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. C. P. Teng, H. H. Chen, J. Chan, and D. C. B. Lye, “Ertapenem for the treatment of extended-spectrum β-lactamase-producing Gram-negative bacterial infections,” International Journal of Antimicrobial Agents, vol. 30, no. 4, pp. 356–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Bilavsky, M. J. Schwaber, and Y. Carmeli, “How to stem the tide of carbapenemase-producing Enterobacteriaceae?: proactive versus reactive strategies,” Current Opinion in Infectious Diseases, vol. 23, no. 4, pp. 327–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Hussein, H. Sprecher, T. Mashiach, I. Oren, I. Kassis, and R. Finkelstein, “Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns,” Infection Control and Hospital Epidemiology, vol. 30, no. 7, pp. 666–671, 2009. View at Publisher · View at Google Scholar · View at Scopus